CG Oncology, Inc. (CGON) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 5.61B USD. 52-week range 35.80 to 80.97 USD. Data as of 2026-10-09.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of ...